ClinicalTrials.gg
RecruitingNCT06601296SPARKUpdated Oct 29, 2026

Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer

A Phase 2 interventional study of IMSA101 in Metastatic Renal Cell Carcinoma ( mRCC) and OligoProgressive Metastatic Disease, sponsored by University of Texas Southwestern Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by University of Texas Southwestern Medical Center · Phase 2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Updated Oct 29, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Carcinoma, Renal Cell by University of Texas Southwestern Medical Center — 5 open to participants now, 6 under way, none of them phase 3. Carcinoma, Renal Cell · University of Texas Southwestern Medical Center.

Started
2025
the only one that year
Phase 2
4 of 10
3 open now
Registered
10th of 10
by date

Among the 10 studies in Carcinoma, Renal Cell by University of Texas Southwestern Medical Center, this one is the only one that started in 2025, is one of 4 in phase 2, and was the 10th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

5 of the 10 studies in Carcinoma, Renal Cell by University of Texas Southwestern Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Carcinoma, Renal Cell by University of Texas Southwestern Medical Center, or all of them as a file.
02

Study summary

To evaluate the impact of combining innate immune system activation (with IMSA101) with antigen release (through SAbR/PULSAR) on limited progressing lesions during ongoing adaptive immune system activation (with maintenance Nivo).

Read the detailed description

The study expects to accrue the 15 patients over a 3-4 year period.

Patients with oligoprogressive disease (up to 5 lesions) after prior treatment with check-point inhibitor monotherapy (Nivolumab or Pembrolizumab). All patients will undergo baseline biopsy (just before the administration of IMSA101 of the same lesion to be injected). SAbR will be delivered in 3 fractions at 12 Gy every 4 weeks (PULSAR regimen) to all progressing lesions. One lesion will also receive 3 intratumoral injections of IMSA101 (C1D1, C2D1, C3D1) immediately after radiation either on the same day or within 72 hours after the PULSE.

Selected Phase 2 dosing of IMSA101 (1200mcg) will be utilized.

At disease progression, patients have the option to undergo additional imaging and tissue/blood collections.

03

Conditions studied

  • Metastatic Renal Cell Carcinoma ( mRCC)
  • OligoProgressive Metastatic Disease

Keywords

  • renal
  • kidney
  • mrcc
  • metastatic
  • cancer
  • STING
  • PULSAR
  • SABr
  • SPARK
  • nivolumab
  • IMSA 101
04

Who can participate

The criteria were revised on the registry on Oct 29, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have ccRCC.
  • Patients must have oligoprogressive disease (up to 5 progressing lesions) on any ongoing or prior check-point inhibitor regimen that are all amenable to radiation including one lesion suitable for IMSA101 injection.
  • Performance Status (KPS) of at least 50%.
  • of at least 6 months.
  • Age ≥ 18 years.
  • Patients must have adequate organ and marrow function within 14 days prior to study entry.
  • All IMDC risk categories are allowed.

Exclusion criteria

Exclusion Criteria:

  • Prior high-grade toxicity from check-point inhibitors deemed to place he patient at high risk for toxicity recurrence with re-challenge with check-point inhibitors.
  • Prior STING agonist use.
  • Any condition requiring systemic treatment with (>10 mg daily prednisone equivalent) or other medications within 14 days prior to first dose of study drug. Inhaled steroids and adrenal replacement steroid doses up to 10 mg daily prednisone equivalents are permitted in the absence of active disease.
  • Uncontrolled adrenal insufficiency.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    SAbR with Intratumoral STING agonist IMSA101 and IO with Anti-PD1

    Only one arm will be maintained in this phase II study with all patients undergoing the following treatment: SOC treatment: Nivolumab 480 mg monthly PULSAR: 36 Gy in 3 fractions, Q4weeks IMSA101: three intra-tumoral injections of one of the progressive lesions at 1200 mcg (C1D1, C2D1, C3D1)

    Drug: IMSA101

Interventions

  • DrugSTING Agonist IMSA101Studies of STING Agonist IMSA101STING Agonist IMSA101 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    All enrolled patients to undergo the following treatment: SOC treatment: Nivolumab 480mg monthly PULSAR: 36 Gy in 3 fractions, Q4weeks IMSA101: three intra-tumoral injections of one of the progressive lesions at 1200 mcg (C1D1, C2D1, C3D1)

This study also gives NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. To evaluate the PFS rate associated with the therapeutic intervention. PFS is defined as the duration of time from initiation of PULSAR/IMSA101 to disease progression as defined by RECIST1.1 or death.

    Exact binomial test will be used to test if the lower limit of the 95% confidence interval of the probability of postponing systemic therapy \>9 months will be greater than 30%.

    Time frame: Time from initiation of PULSAR/IMSA101 until death from any cause. Follow-up visits to be done every 12 weeks (+/- 1 week) for study duration until patient has progressed. Afterward, subjects to be contacted every 6 months for survival data up to 5 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Oct 2027, 30 months after the start.

Of 185 non-industry phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 98. This study's planned 30 months is below that.

Counting every sponsor, half of 232 studies reached it within 58 months; a quarter within 33 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2024
First posted
Sep 19, 2024
StartActual
Apr 1, 2025
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2028
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
2 inclusion criteria added, 3 removed; 4 exclusion criteria added, 1 removed
What changed in the criteria
Inclusion criteria
  • RemovedPatients must have oligoprogression defined as progression in ≤5 lesions.
  • RemovedAll oligoprogression lesions must be suitable for radiation.
  • RemovedPatients must have at least one site of disease that can be safely injected with IMSA101.
  • AddedPatients must have oligoprogressive disease (up to 5 progressing lesions) on any ongoing or prior check-point inhibitor regimen that are all amenable to radiation including one lesion suitable for IMSA101 injection.
  • AddedLife expectancy of at least 6 months.
Exclusion criteria
  • RemovedPatients with progressive ultracentral/central chest lesions will be excluded
  • AddedPrior high-grade toxicity from check-point inhibitors deemed to place he patient at high risk for toxicity recurrence with re-challenge with check-point inhibitors.
  • AddedPrior STING agonist use.
  • AddedAny condition requiring systemic treatment with corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to first dose of study drug. Inhaled steroids and adrenal replacement steroid doses up to 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
  • AddedUncontrolled adrenal insufficiency.
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Eligibility 2 inclusion criteria added, 3 removed; 4 exclusion criteria added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedPatients must have oligoprogression defined as progression in ≤5 lesions.
    • RemovedAll oligoprogression lesions must be suitable for radiation.
    • RemovedPatients must have at least one site of disease that can be safely injected with IMSA101.
    • AddedPatients must have oligoprogressive disease (up to 5 progressing lesions) on any ongoing or prior check-point inhibitor regimen that are all amenable to radiation including one lesion suitable for IMSA101 injection.
    • AddedLife expectancy of at least 6 months.
    Exclusion criteria
    • RemovedPatients with progressive ultracentral/central chest lesions will be excluded
    • AddedPrior high-grade toxicity from check-point inhibitors deemed to place he patient at high risk for toxicity recurrence with re-challenge with check-point inhibitors.
    • AddedPrior STING agonist use.
    • AddedAny condition requiring systemic treatment with corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to first dose of study drug. Inhaled steroids and adrenal replacement steroid doses up to 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
    • AddedUncontrolled adrenal insufficiency.
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06601296
Responsible party
Raquibul Hannan (MD, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Sep 19, 2024
Start date
Apr 1, 2025
Primary completion
Oct 2027 (estimated)
Completion
Oct 2028 (estimated)
Last update
Oct 29, 2026

Study contacts

SARAH NEUFELD, MANAGER OF CLINICAL RESEARCH, MS, MBA
Contact
Sarah.Hardee@UTSouthwestern.edu
214 648 1836
RAQUIBUL HANNAN, MD, PhD.
Contact
Raquibul.Hannan@UTSouthwestern.edu
214 645 7696
RAQUIBUL HANNAN, MD
principal investigator · University of Texas Southwestern Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: STING Agonist IMSA101

Start the discussion